6 h after L-ZnPP dosing. However, rats treated with 1000 pmol of blank liposomes per kg to saturate the reticuloendothelial system 2 h before L-ZnPP administration had splenic heme oxygenase activity of 0.25 + 0.16 nmol CO/ h/mg protein at t = 6 h, which is significantly less than that of the L-ZnPP alone group (p c 0.05). In adult rats treated with heat-damaged red blood cells (RBC) to simulate hemolysis, treatment with 10 pmol of aqueous ZnPP per kg or 10 pmol of untargeted L-ZnPP per kg did not produce a difference from control in total body bilirubin production as estimated by CO excretion. However, RBCtreated rats given 1000 pmol of blank liposomes per kg 2 h before L-ZnPP administration produced significantly less CO than control, aqueous ZnPP-treated, and untargeted L-ZnPP-treated rats from 8 to 12 h after RBC treatment. In addition, splenic heme oxygenase activity in RBCtreated rats receiving 10 pmol of targeted L-ZnPP per kg was completely eliminated 12 h after RBC treatment. These results indicate that targeting of L-ZnPP to the spleen with reticuloendothelial blockade leads to improved in vivo suppression of total body bilirubin production in adult rats treated with heat-damaged RBC. More complete inhibition of splenic heme osygenase is the likely mcchanism for this improved therapeutic effect. (Pediatr Res 34: [1] [2] [3] [4] [5] 1993) Abbreviations ZnPP, zinc protoporphyrin L-ZnPP, liposomal zinc protoporphyrin SnPP, tin protoporphyrin HO, heme oxygenase CO, carbon monoxide VeCO, total body carbon monoxide excretion RES, reticuloendothelial system RBC, red blood cell EPC, egg phosphatidylcholine EPG, egg phosphatidylglycerol i.p., intraperitoneal(1y)
Neonatal hyperbilirubinemia continues to be a common concern, with more than 6% of newborns developing significant jaundice (serum bilirubin above 220 pmol/L) nationwide (1). Bilirubin is produced from heme by a two-step pathway of which HO (EC 1.14.99.3) is the rate-limitingenzyme (2). In the neonate, bilirubin produced in the RES from senescent fetal RBC cannot be excreted by the immature conjugating mechanisms of the neonatal liver, leading to blood bilirubin levels far above those of normal adults. Severe neonatal hyperbilirubinemia is associated with kernicterus and death, although the pathophysiology of this process is still being studied and debated (3) (4) (5) (6) . Current treatments for neonatal jaundice, such as phototherapy, focus on increasing the clearance of bilirubin from the blood. An experimental treatment for neonatal jaundice is being investigated that would use analogs of heme to competitively inhibit HO (7, 8) . This approach is attractive because elevated bilirubin levels can be prevented.
A variety of metalloporphyrin HO inhibitors have been studied in several animal models (7-1 I). The first trial of SnPP in human neonates (12) , however, was clinically unremarkable (13) . Perhaps this was because insufficient amounts of metalloporphyrin were available to heme-degrading tissues of the RES at the low doses of 1-2 pmol SnPP per kg used in that study. One obvious way to increase the drug localized to the RES would be to increase the dose. However, this might lead to an increase in adverse reactions as well. Liposomal incorporation may make it possible to increase the amount of porphyrin localized to the RES without dose escalation.
Liposomes are artificial lipid vesicles with one or more concentric bilayers composed mainly of phospholipid and cholesterol. ~h e~-c a n be used to encapsulate drugs in the aqueous volume, the lipid bilayer itself, or a combination of both (14) . Their usefulness for the delivery of many drugs has been limited because most liposomes are quickly scavenged by RES (15 duct-cannukited rats treated with liposomal tin mesoporphyrin.
ZnPP LIPOSOMES TARGETED TO THE SPLEEN 3 kg. Bihourly VeCO readings were then performed until CO excretion returned to near baseline levels. Animals that had been given damaged RBC were killed at t = 12 h and assayed for HO activity in the liver and spleen. Sratisfics. The data are expressed as a mean 2 SD; the number of determinations is given in parentheses. Data were analyzed using a one-way analysis of variance. Statistical differences between groups were determined using the Scheffe F-test. Table 1 shows the encapsulation of ZnPP into liposomes by the ethanol injection method. The optimum encapsulated drug to lipid ratio was about 1:16, allowing greater than 90% of the drug to be encapsulated with no need for free drug removal. The 0ctanol:water partition coefficient of ZnPP was found to be 3.2 +. 0.2 (not shown), which indicates that most of the encapsulated ZnPP is located in the bilayer of the liposomes (17) .
RESULTS
The effect of targeting ZnPP liposomes to the spleen of adult rats without hemolysis is shown in Table 2 . The HO activity in the spleens and livers of both L-ZnPP-treated groups was significantly ( p < 0.01) lower than that of the controls. In addition, the splenic HO activity in the rats receiving a predose of blank liposomes to saturate the RES was significantly ( p < 0.05) lower than that of animals who had received a predose of saline before administration of L-ZnPP. Six h after L-ZnPP administration, the VeCO of the saline-pretreated group had dropped to 79% of its initial value, and the VeCO of the liposome-pretreated group had dropped to 72% of its initial value. The VeCO of the control group did not change over this time period. The difference in VeCO between the two L-ZnPP-treated groups and the control group was significant at p < 0.0 1. Figure IA shows the results of the VeCO readings of animals that had been treated with an i.p. dose of hemin to simulate hemolysis. An initial rise in the VeCO was seen in all animals. Administration of L-ZnPP at t = 2 h blocked further rises in the VeCO over the next 10 h. L-ZnPP-treated rats, pretreated with saline, produced significantly (p < 0.01) less CO than liposometreated controls at t = 6 and t = 8 h. L-ZnPP-treated rats pretreated with the blank liposomes produced significantly less CO than controls from t = 4 to t = 8 h. Aqueous ZnPP at a dose of 10 pmollkg administered at t = 2 h produced no statistical difference from control in this model. Both groups of animals dosed with L-ZnPP showed statistical difference ( p < 0.01) from the aqueous ZnPP-treated group, the saline-predosed group at t = 8 h, and the liposome-predosed group a t = 4, 6, and 8 h. There was no statistical difference between L-ZnPP-treated rats predosed with saline, and those predosed with an RES saturating dose of blank liposomes over the course of this experiment.
Figure 1 B shows the results of VeCO determinations in animals treated with damaged RBC to simulate hemolysis. All rats given damaged RBC showed a rapid rise in the VeCO. Animals given a pretreatment of blank liposomes to saturate the RES 2 h before L-ZnPP showed a more rapid decline in VeCO from t = 6 to 12 h than did control, aqueous ZnPP-treated, or salinepretreated L-ZnPP-treated animals. Lipid-pretreated animals produced significantly ( p C 0.05) less CO at t = 8, 10, and 12 h after RBC treatment compared with all other groups. Table 3 shows the liver and spleen HO activity of the animals from Figure 1B killed at t = 12 h. All ZnPP-treated groups had significantly decreased liver HO activity relative to controls. In addition, both L-ZnPP-treated groups had significantly decreased splenic HO activity relative to controls. In the lipid pretreated group, splenic HO activity was completely eliminated. (1 8,22,23 ) has been extensive. This article provides the second report of the use of porphyrins and liposomes toward the goal of preventing jaundice in neonates. We have shown that ZnPP can be incorporated into liposomes of EPC and EPG with good efficiency by both the ethanol injection and thin film methods. Our thin film preparations were easily extruded to 0.3 pm without loss of drug or encapsulation efficiency. Because the negatively charged EPG was included in the bilayer, our liposomal suspension did not aggregate even after a week of storage, and our experience with other negatively charged preparations leads us to believe that this formulation could be stored much longer. Furthermore, when prepared with the proper cryoprotectant, we have found that similar preparations are easily lyophilized, increasing shelf-life dramatically. In contrast, neutral EPC preparations are in general quite unstable and would be expected to form uninjectable aggregates in a matter of days.
In adult rats without hemolysis, a dose of 10 pmol L-ZnPP per kg suppressed the VeCO and liver and spleen HO activity to a level comparable to that reached using an aqueous dose of 40 pmol ZnPP per kg (10). Our results also indicate that reticuloendothelial blockade with blank liposomes 2 h before administration of L-ZnPP increases the degree to which splenic HO is inhibited. Interestingly, it was difficult to correlate this increased splenic HO inhibition with increased therapeutic efficacy as reflected by suppression of the VeCO.
We believe that, because bilirubin production in the adult rat without hemolysis is rather limited, this model was not sensitive enough for us to discern a true difference. Yet, the results also indicate that there was essentially no benefit seen due to targeting of ZnPP to the spleen in the inhibition of the VeCO of adult rats when i.p. hemin was given to simulate hemolysis. However, when damaged RBC were injected i.v. as a hemolytic challenge, the results were strikingly different. Liposomal ZnPP produced no difference from control unless a pretreatment of blank liposomes was given to saturate the RES. This raises the question of which of these two hemolytic models is more representative of jaundice in the neonate.
Serum albumin is a well-described camer of endogenous porphyrins. Yet, few studies of the pharmacodynamics of injected exogenous porphyrins have been reported. The photosensitizer hematoporphyrin injected as an aqueous solution associates heavily with plasma lipoproteins, especially HDL, in which it can circulate for extended periods of time (23) . Other evidence indicates that hemopexin would carry a substantial portion of SnPP injected as an aqueous solution (24) . The degree of porphyrin association with lipoproteins and hemopexin is related to iniection liposomes of vary in^ formzrlation* [Lipid] [ Two h later, animals were given 10 pmol L-ZnPP per kg or an equal volume of blank liposomes. Six h later, the VeCO was again measured, and the animals were killed and assayed for HO in the indicated tissues.
t p < 0.01 relative to controls, Scheffe F-test.
4 p < 0.05 relative to the saline-pretreated group, Scheffe F-test. hydrophobicity (23, 24) . Because hemin, like SnPP and hematoporphyrin, is hydrophobic, it likely would associate with plasma lipoproteins and hemopexin after injection and would be cleared from the circulation by the hepatocyte, not the RES macrophage. Thus, injection of aqueous hemin would preferentially stimulate liver, specifically hepatocyte, HO activity. In contrast, heat-damaged RBC are cleared from the circulation by the macrophages of the RES, particularly those in the spleen (20) . A similar mechanism is responsible for clearing damaged RBC from the circulation of the neonate with hemolytic disease (1). Thus, injection of heat-damaged RBC into the rat is probably a better model for studying neonatal jaundice than injection of aqueous hemin. When we focus only on the results of the VeCO readings in animals treated with damaged RBC, we see a clear benefit of targeting ZnPP to the spleen.
In general, we have demonstrated more complete inhibition of liver HO activity than of splenic HO activity in vivo with administration of aqueous ZnPP (10, 1 1). As mentioned earlier, this is probably due to delivery of the majority of injected porphyrin to the hepatocyte by hemopexin and lipoproteins. However, a large portion of the heme from senescent RBC is probably converted to bilirubin in the spleen (1). In the present study, the splenic HO activity that was not eliminated in the aqueous ZnPP-treated group and the saline-predosed L-ZnPPtreated group from Figure 1B was evidently enough to allow those animals to keep pace with controls as far as total body CO production. Because the splenic H O activity of the liposomepretreated rats represented in Figure 1 B was totally eliminated, a significant decrease in total CO production was observed from t = 8 to 12 h relative to the other three groups. These results confirm the hypothesis of Landaw et al. (16) that delivery of adequate porphyrin to the spleen represents a major stumbling block to the optimum use of metalloporphyrin HO inhibitors as a therapy for neonatal jaundice.
We have demonstrated in a rodent model that active targeting of L-ZnPP to the spleen using reticuloendothelial blockade can increase HO inhibition there, with a corresponding decrease in VeCO when damaged RBC are injected as a hemolytic challenge. This targeting method, however, is cumbersome and might have adverse consequences, such as increased risk of infection in the high-risk neonate. Recent work using sterically stabilized liposomes with extended blood circulation times (Stealth liposomes, Liposome Technology, Inc., Menlo Park, CA) has shown that almost 50% of an injected dose of large liposomes can be Z n P P LIPOSOMES T A R ( 3 E T E D TO T H E S P L E E N 5 delivered to the spleen, with most of the balance being delivered to the liver and less than 10% going to other tissues (25, 26). This phenomenon depends on the size of the liposome and the use of special lipids in the bilayer (27). The use of Stealth liposomes to encapsulate relatively lipid-soluble metalloporphyrin inhibitors of HO such as ZnPP might increase the potency of these drugs by allowing maximum delivery of inhibitor to heme-degrading tissues. At the same time, porphyrin would not be delivered to tissues where it might cause adverse reactions. We would predict large increases in the therapeutic efficacy of these drugs were this proved to be the case.
